Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis

Reuters2026/08/24 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vanda won European Commission orphan designation for imsidolimab to treat generalized pustular psoriasis, a rare, potentially life-threatening inflammatory skin disease.
The FDA is reviewing the imsidolimab BLA for generalized pustular psoriasis, with an action date of Dec. 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608240700PR_NEWS_USPR_____PH31792) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis

You may also like

Crypto prices